Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-05-07
Tempus AI, Inc.
Tempus provides genomic diagnostics, clinical workflow software, and governed multimodal data and analytics products to physicians, health systems, and life sciences customers.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

A data-rights moat chasing platform economics
The core question is whether a fast-growing precision-medicine business can convert lab volume into sticky workflow and data revenue before reimbursement and capital needs cap its valuation. The path looks credible enough for strong compounding, but not loose enough for a moonshot label.

Analysis

Thesis
Tempus can compound well above healthcare norms if it keeps turning each test ordered into higher-value governed data, workflow, and life-science revenue while improving reimbursement and removing balance-sheet friction.
Last Economy Alignment
AI makes interpretation cheaper, but Tempus owns harder control points: rights-cleared clinical data, embedded ordering workflows, and compliance gates. Its software surface has some commoditization risk, yet value capture is not mainly seat-based and switching costs are supported by data, trust, and clinical embed.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.8x (from 5 most recent analyses)
Reasoning
The upside does not require a heroic rerating. The company already has real demand, and the key question is mix: whether diagnostics volume keeps feeding a larger share of higher-value data, workflow, and evidence products. If that happens while reimbursement improves and refinancing reduces drag, Tempus can compound strongly even if investors still apply a disciplined healthcare multiple.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is economic conversion, not product novelty. Tempus must turn strong testing growth and governed data assets into durable, self-funding workflow and licensing economics before reimbursement delays, regulatory gates, or capital needs force investors to value it like a good lab instead of a higher-quality healthcare operating layer.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.59
They control hard-to-recreate patient data rights and sit inside the testing and workflow loop that creates more data every time doctors use them. Generic AI can copy assistant features, but it cannot easily copy the governed data, trust, and reimbursement plumbing needed to get paid in healthcare.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$72.46
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case